Please wait while we load the requested 10-Q report or click the link below:
https://last10k.com/sec-filings/report/1411906/000155837021015493/ampe-20210930x10q.htm
SEC Filings
AMPE Annual Reports
10-K Annual Report March 2023
10-K Annual Report March 2022
10-K Annual Report March 2021
10-K Annual Report February 2020
10-K Annual Report March 2019
10-K Annual Report March 2018
10-K Annual Report March 2017
10-K Annual Report February 2016
10-K Annual Report February 2015
10-K Annual Report February 2014
10-K Annual Report March 2023
10-K Annual Report March 2022
10-K Annual Report March 2021
10-K Annual Report February 2020
10-K Annual Report March 2019
10-K Annual Report March 2018
10-K Annual Report March 2017
10-K Annual Report February 2016
10-K Annual Report February 2015
10-K Annual Report February 2014
AMPE Quarterly Reports
AMPE Corporate News
Financial Exhibit
New Agreement September 2023
Bylaw Change
Financial Exhibit
Other Events August 2023
Event for Officers
Financial Exhibit
Security Holders Change
Vote of Security Holders July 2023
Other Events July 2023
Bylaw Change
Financial Exhibit
Regulated Disclosure
Security Holders Change May 2023
Financial Exhibit
Regulated Disclosure April 2023
Regulated Disclosure March 2023
Ending Agreement March 2023
Financial Exhibit
Regulated Disclosure January 2023
Financial Exhibit
Regulated Disclosure December 2022
Financial Exhibit
New Agreement
New Agreement
September 2023
Bylaw Change
Financial Exhibit
Other Events
Financial Exhibit
Other Events
August 2023
Event for Officers
Financial Exhibit
Security Holders Change
Vote of Security Holders
Financial Exhibit
Security Holders Change
Vote of Security Holders
July 2023
Other Events
July 2023
Bylaw Change
Financial Exhibit
Regulated Disclosure
Security Holders Change
Financial Exhibit
Regulated Disclosure
Security Holders Change
May 2023
Financial Exhibit
Regulated Disclosure
Regulated Disclosure
April 2023
Regulated Disclosure
March 2023
Ending Agreement
March 2023
Financial Exhibit
Regulated Disclosure
Regulated Disclosure
January 2023
Financial Exhibit
Regulated Disclosure
Regulated Disclosure
December 2022
Last10K.com | 10-Q Quarterly Report Wed Nov 10 2021
Ampio Pharmaceuticals, Inc. Announces Second Quarter 2021 Financial Results and Provides Corporate Update
Further details to be discussed on this afternoon’s conference call
ENGLEWOOD, CO, August 4, 2021 – Ampio Pharmaceuticals, Inc. (NYSE American: AMPE), a biopharmaceutical company focused on the advancement of immunology-based therapies for prevalent inflammatory conditions for which there are limited treatment options, today reported results for the second quarter period ended June 30, 2021, and provided a corporate overview and business update.
Mr. Michael Macaluso, President and Chief Executive Officer, commented, “This was an exciting quarter for Ampio, and I am proud of our accomplishments over the past three months. We completed our Phase I trial utilizing inhaled Ampion for COVID-19 patients with respiratory distress, which showed that Ampion reduced all-cause mortality by 78% over the Standard of Care. On the basis of those results, during the current quarter we worked with the Federal Drug Administration (FDA) to initiate Phase II trials utilizing inhaled Ampion and intravenous (IV) Ampion for COVID-19 patients with respiratory distress that may support an Emergency Use Authorization (EUA). We have commenced enrollment, which we expect to see incrementally increase in the near term as a result of expanding the inhaled Ampion Phase II study to India, which had, and is continuing to experience, a significant wave of serious COVID-19 infections. Additionally, we are exploring the first at-home inhalation treatment for long COVID patients in a Phase I study utilizing inhaled Ampion. The study is currently enrolling and could represent a significant breakthrough in patient care.”
“Ampio Pharmaceuticals has joined the Russell 2000® and Russell 3000® Indexes,” continued Macaluso, “which I take as a sign that the market now understands the broad potential of Ampion as a platform anti-inflammatory treatment for patients with unmet medical needs.”
Mr. Michael Macaluso, President and Chief Executive Officer, Dr. David Bar-Or, Director and Founder, Ms. Holli Cherevka, Chief Operating Officer and Mr. Daniel Stokely, Chief Financial Officer will be hosting a Conference Call for the Investment Community this afternoon beginning at 4:30 PM ET (see details below).
The key areas of focus during the call will be as follows:
| ● | Osteoarthritis of the Knee (OAK) Clinical Trial 2021 Timeline / Update |
| ● | COVID-19 Platform / Pipeline Overview and Update |
| ● | Update on Other Pre-Clinical Research Programs |
The following information was filed by Ampio Pharmaceuticals, Inc. (AMPE) on Wednesday, August 4, 2021 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-Q Quarterly Report statement of earnings and operation as management may choose to highlight particular information in the press release.
View differences made from one quarter to another to evaluate Ampio Pharmaceuticals, Inc.'s financial trajectory
Compare this 10-Q Quarterly Report to its predecessor by reading our highlights to see what text and tables were removed , added and changed by Ampio Pharmaceuticals, Inc..
Assess how Ampio Pharmaceuticals, Inc.'s management team is paid from their Annual Proxy
Ampio Pharmaceuticals, Inc.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2021 10-K Annual Report includes:
- Voting Procedures
- Board Members
- Executive Team
- Salaries, Bonuses, Perks
- Peers / Competitors
SEC Filing Tools
Rating
Learn More
Filter Sentiment:
Filter Category:
Filter Subcategory:
-
Financial - Shares Highlight
Our shelf registration statement, which was declared effective by the SEC in May 2020, provides us with the ability to sell up to an aggregate amount of $100.0 million of shares of common stock, preferred stock, debt securities, warrants and units, or any combination thereof, less any sales from the ATM equity offering program that occurred prior to May 6, 2020, which was the effective date of the shelf registration statement.
-
Financial - Expense Highlight
General and Administrative General and administrative expenses are summarized as follows: 2021 Quarter Compared to 2020 Quarter General and administrative costs decreased $0.4 million, or 24%, for the 2021 quarter compared to the 2020 quarter.
-
Other - Other Highlight
Specifically, mortality in the SOC group was 24%, while in the group treated with Ampion and SOC, mortality was only 5%, representing an almost 80% improvement.
-
Financial - Expense Highlight
31 Insurance Insurance expense decreased $79,000, or 23%, for the 2021 quarter compared to the 2020 quarter due primarily to a decrease in our D&O insurance premiums as a result of favorable negotiations with the insurance carriers, which were influenced by the dismissal of the securities class action and derivative cases during the third quarter of 2020.
-
Financial - Shares Highlight
During the nine months ended September 30, 2021, we sold approximately 6.2 million shares of common stock pursuant to the ATM equity offering program, which yielded gross proceeds of approximately $10.5 million; offset by offering related costs of $0.5 million.
-
Other - Other
Due to its mode of...Read more
-
Financial - Expense
Clinical trial and sponsored research...Read more
-
Other - Other
As an immunomodulatory agent, we...Read more
-
Financial - Expense
The biopharmaceutical market, both domestic...Read more
-
Other - Other
This could lead to impairment...Read more
-
Other - Other
Elevated levels of inflammatory cytokines...Read more
-
Revenue - Product
During the nine months ended...Read more
-
Financial - Expense
Clinical trial and sponsored research...Read more
-
Other - Other
As an immunomodulatory agent, with...Read more
-
Financial - Shares
Based on our current cash...Read more
-
Other - Other
32 During the nine months...Read more
-
Other - Other
Other key findings from the...Read more
-
Other - Other
The outstanding amount of investor...Read more
-
Financial - Expense
Operations / manufacturing Operations /...Read more
-
Other - Other
For additional information regarding these...Read more
-
Financial - Expense
Stock-based Compensation Stock-based compensation expense...Read more
-
Other - Other
We believe it is imperative...Read more
-
Financial - Expense
2021 Period Compared to 2020...Read more
-
Financial - Shares
In May 2020, the shelf...Read more
-
Other - Other
In late 2020, we announced...Read more
-
Financial - Expense
Stock-based Compensation Stock-based compensation expense...Read more
-
Other - Other
However, during the nine months...Read more
-
Other - Other
Due to its mode of...Read more
-
Other - Other
In March 2020, and most...Read more
-
Other - Other
Patients treated with Ampion were...Read more
-
Financial - Expense
Research and development costs with...Read more
-
Financial - Expense
30 Operations / manufacturing Operations...Read more
-
Financial - Expense
Research and development costs with...Read more
-
Financial - Expense
Laboratory Laboratory expenses increased $402,000,...Read more
-
Other - Other
While we believe the studies...Read more
-
Financial - Expense
General and administrative costs with...Read more
-
Financial - Expense
General and administrative costs with...Read more
-
Financial - Expense
Laboratory Laboratory expenses increased $208,000,...Read more
Financial Statements, Disclosures and Schedules
Inside this 10-Q Quarterly Report
Document And Entity Information
Condensed Balance Sheets
Condensed Balance Sheets (Parenthetical)
Condensed Statements Of Cash Flows
Condensed Statements Of Operations
Condensed Statements Of Stockholders' Equity
Accounts Payable And Accrued Expenses
Accounts Payable And Accrued Expenses (Detail)
Accounts Payable And Accrued Expenses (Tables)
Accounts Payable And Accrued Expenses - Commercial Insurance Premium Financing Agreement (Detail)
Commitments And Contingencies
Commitments And Contingencies (Tables)
Commitments And Contingencies - Additional Information (Detail)
Commitments And Contingencies - Employment Agreements (Detail)
Commitments And Contingencies - Lease Expense (Detail)
Commitments And Contingencies - Summary Of Commitments And Contingencies (Detail)
Commitments And Contingencies - Summary Of Reconciliation Of Company's Undiscounted Payments For Facility Lease And Carrying Amount Of Lease Liability (Detail)
Common Stock
Common Stock (Common Stock Issued For Services) (Detail)
Common Stock (Sales Agreement) (Detail)
Common Stock (Summarizes The Company's Remaining Authorized Shares Available - (Detail)
Common Stock (Tables)
Earnings Per Share
Earnings Per Share (Detail)
Earnings Per Share (Tables)
Earnings Per Share - Anti-Dilutive (Detail)
Equity
Equity (Tables)
Equity - Activity Of Plan (Detail)
Equity - Assumptions Used In Computing Fair Value Of All Options Granted (Detail)
Equity - Stock Option Activity (Detail)
Equity - Summary Of Stock Options Outstanding And Exercisable (Detail)
Equity - Summary Of Stock-Based Compensation Expense (Detail)
Fair Value Considerations
Fair Value Considerations (Tables)
Fair Value Considerations - Financial Assets And Liabilities (Detail)
Fair Value Considerations - Sets Forth A Reconciliation Of Changes (Detail)
Fixed Assets
Fixed Assets (Detail)
Fixed Assets (Tables)
Fixed Assets - Depreciation And Amortization Expense (Detail)
Going Concern
Going Concern (Detail)
Litigation
Paycheck Protection Program
Paycheck Protection Program - Additional Information (Detail)
Prepaid Expenses And Other
Prepaid Expenses And Other (Detail)
Prepaid Expenses And Other (Tables)
Subsequent Events
Subsequent Events - (Detail)
The Company And Summary Of Significant Accounting Policies
The Company And Summary Of Significant Accounting Policies (Policies)
Warrants
Warrants (Tables)
Warrants - Narrative (Detail)
Warrants - Warrants Activity (Detail)
Warrants - Warrants Activity Classified As Equity And Liability (Detail)
Material Contracts, Statements, Certifications & more
Ampio Pharmaceuticals, Inc. provided additional information to their SEC Filing as exhibits
Ticker: AMPE
CIK: 1411906
Form Type: 10-Q Quarterly Report
Accession Number: 0001558370-21-015493
Submitted to the SEC: Wed Nov 10 2021 4:13:36 PM EST
Accepted by the SEC: Wed Nov 10 2021
Period: Thursday, September 30, 2021
Industry: Pharmaceutical Preparations
External Resources:
Stock Quote
Social Media
SEC.gov
Bookmark the Permalink: https://last10k.com/sec-filings/ampe/0001558370-21-015493.htm
SEC Filing Exhibit
PDF Download
Loading SEC Filing Exhibit...
Excel DownloadLoading SEC Filing Financial Summary...